Health Catalyst, Inc. (NASDAQ:HCAT) Receives $11.42 Average Price Target from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has been given an average rating of “Moderate Buy” by the twelve analysts that are presently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $11.42.

A number of research firms recently commented on HCAT. Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 price target on shares of Health Catalyst in a report on Tuesday, May 21st. Evercore ISI lowered their target price on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, July 9th. JPMorgan Chase & Co. upped their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a report on Tuesday, August 20th. Finally, Piper Sandler dropped their target price on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th.

Health Catalyst Stock Performance

Shares of NASDAQ HCAT opened at $8.70 on Wednesday. The business has a fifty day moving average of $7.14 and a two-hundred day moving average of $6.89. Health Catalyst has a 52-week low of $5.42 and a 52-week high of $11.41. The stock has a market cap of $513.60 million, a PE ratio of -4.70 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. The firm had revenue of $75.90 million for the quarter, compared to analyst estimates of $74.96 million. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.21) earnings per share. Analysts predict that Health Catalyst will post -0.35 earnings per share for the current year.

Insider Activity at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Monday, August 5th. The shares were sold at an average price of $6.19, for a total transaction of $32,243.71. Following the completion of the sale, the chief operating officer now owns 150,006 shares of the company’s stock, valued at approximately $928,537.14. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $6.19, for a total transaction of $32,243.71. Following the completion of the transaction, the chief operating officer now directly owns 150,006 shares in the company, valued at approximately $928,537.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. The disclosure for this sale can be found here. Insiders have sold 34,037 shares of company stock worth $236,872 over the last ninety days. Company insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors and hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its holdings in Health Catalyst by 461.0% during the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after acquiring an additional 5,232 shares in the last quarter. Quarry LP raised its position in shares of Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares during the period. Perfromance Wealth Partners LLC acquired a new stake in shares of Health Catalyst during the second quarter worth about $64,000. Mackenzie Financial Corp acquired a new position in shares of Health Catalyst in the 2nd quarter valued at approximately $70,000. Finally, EntryPoint Capital LLC bought a new stake in Health Catalyst during the 1st quarter worth approximately $98,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.